New Capsule Now Implemented in Ongoing RA Study; AD Study Transition Planned Following the positive bioequivalence data, LAPIX has successfully transitioned patients in its Phase Ib RA study to the ...
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback